TMDX Key Statistics, Chart & Performance
The current stock price of TMDX is 122.69 USD. In the past month the price decreased by -12.43%. In the past year, price increased by 77.58%.
TMDX Latest News, Press Relases and Analysis
TMDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.89 | 215.95B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.27 | 199.22B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.11 | 140.40B | ||
| SYK | STRYKER CORP | 26.44 | 133.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.52 | 55.64B | ||
| IDXX | IDEXX LABORATORIES INC | 53.13 | 53.50B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.2 | 49.52B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.04 | 37.73B | ||
| RMD | RESMED INC | 24.73 | 35.73B | ||
| DXCM | DEXCOM INC | 35.77 | 25.95B | ||
| PODD | INSULET CORP | 61.91 | 19.90B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.13 | 17.84B |
Related stock screener links
About TMDX
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810 US
CEO: Waleed H. Hassanein
Employees: 728
Phone: 19785520900
TRANSMEDICS GROUP INC / TMDX FAQ
Can you describe the business of TRANSMEDICS GROUP INC?
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Can you provide the latest stock price for TRANSMEDICS GROUP INC?
The current stock price of TMDX is 122.69 USD. The price increased by 0.85% in the last trading session.
Does TRANSMEDICS GROUP INC pay dividends?
TMDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TMDX stock?
TMDX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is TRANSMEDICS GROUP INC (TMDX) expected to grow?
The Revenue of TRANSMEDICS GROUP INC (TMDX) is expected to grow by 39.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does TRANSMEDICS GROUP INC (TMDX) report earnings?
TRANSMEDICS GROUP INC (TMDX) will report earnings on 2026-02-25, after the market close.
Can you provide the ownership details for TMDX stock?
You can find the ownership structure of TRANSMEDICS GROUP INC (TMDX) on the Ownership tab.
TMDX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX is one of the better performing stocks in the market, outperforming 92.73% of all stocks.
TMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TMDX. TMDX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
TMDX Financial Highlights
Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 162.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.2% | ||
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| Debt/Equity | 1.43 |
TMDX Forecast & Estimates
20 analysts have analysed TMDX and the average price target is 148.84 USD. This implies a price increase of 21.31% is expected in the next year compared to the current price of 122.69.
For the next year, analysts expect an EPS growth of 163.67% and a revenue growth 39.67% for TMDX